Omisson (Dienogest, Ethinylestradiol)

Dienogest, the active ingredient in Omisson, is a synthetic progestogen presented as a combined oral tablet for systemic hormonal use. It treats estrogen‑dependent conditions, primarily menstrual cycle disorders, in women of reproductive age. GNH USA supplies Omisson as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Omisson as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Omisson combines Dien­​d​enogest and Ethinylestradiol to address the hormonal regulation pathway in women. It is indicated for: - Dysmenorrhea: Reduces menstrual pain and cramping by stabil the endometrial lining. - Contraception: Provides reliable combined hormonal birth control to prevent ovulation. - Menstrual‑cycle disorder management : Improves cycle regularity and reduces heavy bleeding. - Endometriosis treatment : Alleviates pain and limits growth of endometrial‑like tissue. - Acne treatment : Dimin the influence of androg ‑ like effects on skin sebaceous glands. - Polycystic ovary syndrome (PCOS sym sym ​  ​  ​  ​  ​  ​  ​  ​  ​  ) :  

Common Side Effects: -   -   -  . -  . - ‑  . -  .

Serious or Rare ...

Intro ... 

...